리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 07월
페이지 정보:영문 383 Pages
라이선스 & 가격 (부가세 별도)
한글목차
프로게스테론 세계 시장은 2030년까지 26억 달러에 달할 전망
2024년에 13억 달러로 추정되는 프로게스테론 세계 시장은 2024년부터 2030년까지 CAGR 12.7%로 성장하여 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 천연 프로게스테론은 CAGR 14.7%를 기록하며 분석 기간 종료까지 17억 달러에 달할 것으로 예측됩니다. 합성 프로게스테론 분야의 성장률은 분석 기간 동안 CAGR 9.5%로 추정됩니다.
미국 시장은 3억 4,630만 달러로 추정되는 한편 중국은 CAGR 17.4%로 성장할 것으로 예측되는
미국의 프로게스테론 시장은 2024년에 3억 4,630만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 17.4%로 추정되며, 2030년까지 5억 5,980만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 9.1%와 11.5%로 예측됩니다. 유럽에서는 독일이 CAGR 10.1%로 성장할 것으로 예측됩니다.
세계 프로게스테론 시장 - 주요 동향 및 촉진요인 요약
프로게스테론이 호르몬 요법과 생식 의학에서 점점 더 중요해지는 이유는 무엇일까?
프로게스테론은 호르몬 대체요법(HRT), 불임 치료, 임신 지원 등에 널리 사용되며 제약 산업에서 중요한 호르몬으로 자리 잡았습니다. 프로게스테론은 생리주기, 임신 유지, 생식 건강 전반에 관여하는 중요한 호르몬으로 불임, 다낭성난소증후군(PCOS), 갱년기, 자궁내막증 등의 증상에 처방되고 있습니다. 또한, 고위험 임신의 조산 위험 감소에도 중요한 역할을 하고 있습니다. 호르몬 불균형과 생식 관련 건강 장애의 유병률 증가로 인해 경구용 캡슐, 주사제, 질 젤, 크림 등 프로게스테론 기반 의약품에 대한 수요가 증가하고 있습니다. 체외수정(IVF)과 같은 보조생식술(ART)을 선택하는 여성들이 증가하고 있는 것도 시장 성장을 더욱 촉진하고 있습니다. 프로게스테론은 생식 의학 외에도 신경 보호, 뼈 건강, 암 치료의 잠재적 이점을 위해 연구되고 있습니다. 합성 및 생물학적 프로게스테론 제제의 발전으로 시장은 지속적으로 확대되고 있으며, 다양한 의료 수요를 충족시키고 환자 치료 결과를 개선하고 있습니다.
프로게스테론 요법의 보급에 영향을 미치는 과제는 무엇인가?
프로게스테론 시장은 중요한 의료 용도에도 불구하고 접근성, 경제성, 환자 순응도에 영향을 미치는 몇 가지 과제에 직면해 있습니다. 주요 우려 사항 중 하나는 프로게스테론 요법에 따른 부작용으로 복부 팽만감, 기분 저하, 두통, 피로감 등이 있으며, 일부 환자들은 치료를 중단하기도 합니다. 또한, 특정 프로게스테론에 기반한 불임 치료나 호르몬 대체요법은 고가이기 때문에 특히 의료비 부담이 우려되는 중저소득 지역에서는 접근성이 떨어집니다. 또한, 호르몬 요법을 둘러싼 규제 상황도 과제로 대두되고 있으며, 각국 정부는 의약품의 안전성과 유효성을 확보하기 위해 엄격한 가이드라인을 부과하고 있어 새로운 제제의 승인까지 소요되는 기간이 길어지고 있습니다. 또한, 시장은 대체 호르몬 요법 및 천연 보충제와의 경쟁에 직면하고 있으며, 일부 환자들은 기존 프로게스테론 의약품 대신 식물 유래 및 바이오 아이덴티티 대체품을 선택하기도 합니다. 이러한 문제를 해결하기 위해서는 보다 안전하고 내약성이 우수한 제제에 대한 지속적인 연구, 제네릭 의약품을 통한 경제성 개선, 환자 교육 강화로 치료 순응도와 치료 효과를 높이기 위한 환자 교육이 필요합니다.
약물전달과 바이오 아이덴티티 호르몬의 혁신은 프로게스테론 요법을 어떻게 변화시키고 있는가?
제약 기술과 호르몬 합성의 발전은 프로게스테론 치료에 혁명을 가져왔고, 치료를 보다 효과적이고 편리하며 환자 친화적으로 만들었습니다. 체내 천연 호르몬 구조를 모방한 바이오 아이덴티티 프로게스테론의 개발로 합성 대체품에 비해 내약성이 향상되고 부작용의 위험이 감소했습니다. 경피 패치, 서방형 임플란트, 설하정 등 새로운 약물전달 시스템은 보다 편리한 투여 방법과 지속적 효과로 환자의 순응도를 향상시키고 있습니다. 또한, 자궁내피임기구(IUD)의 도입은 특히 자궁내막증이나 월경과다 출혈을 관리하는 여성들에게 장기적인 피임 및 치료 효과를 가져다주고 있습니다. 의약품 제형에 나노기술을 통합하여 프로게스테론의 생체 이용률을 향상시켜 더 적은 용량으로 더 나은 흡수와 효과를 보장합니다. 맞춤형 의료의 발전에 따라 개인별 호르몬 프로파일에 따라 프로게스테론 치료를 조정하기 위해 AI를 활용한 호르몬 치료의 맞춤화가 검토되고 있습니다. 이러한 기술 혁신은 환자의 예후를 개선할 뿐만 아니라, 생식 및 호르몬 건강 관리에서 프로게스테론 기반 치료법의 시장 잠재력을 확대하고 있습니다.
프로게스테론 시장 성장의 원동력은?
프로게스테론 시장의 성장은 호르몬 장애의 유병률 증가, 보조생식술에 대한 수요 증가, 바이오 아이덴티티 호르몬 요법의 발전 등 여러 가지 요인에 의해 주도되고 있습니다. 생식 의료에 대한 인식이 높아지고 전 세계적으로 불임 치료 클리닉이 확대되면서 프로게스테론 기반 치료 수요에 크게 기여하고 있습니다. 또한, 프로게스테론이 갱년기 관련 증상 관리에 중요한 역할을 하기 때문에 고령 여성들 사이에서 갱년기 호르몬 요법을 채택하는 사례가 증가하고 있으며, 이는 시장 확대에 박차를 가하고 있습니다. 또한, 임산부의 건강 및 임신 관리를 지원하는 정부의 노력과 헬스케어 프로그램, 특히 조산 위험에 대한 대응도 시장 성장을 가속화하고 있습니다. 일반의약품(OTC) 크림과 보충제의 가용성이 높아지면서 호르몬 지원 제품에 대한 소비자의 접근성이 더욱 확대되고 있습니다. 신경학 및 종양학에서 프로게스테론의 잠재적 역할 등 프로게스테론의 새로운 치료적 용도에 대한 연구가 진행됨에 따라 프로게스테론 시장은 지속적으로 성장하여 다양한 건강 상태에 대한 혁신적이고 개인화된 솔루션을 제공할 것으로 예상됩니다.
부문
유형(천연 프로게스테론, 합성 프로게스테론), 제공 방식(주사 기반 제공 방식, 현탁액 기반 제공 방식, 경구 제공 방식), 용도(피임 용도, 자궁내막암 용도, 기능 부전성 자궁 출혈 용도, 과형성 전구 병변 용도, 갱년기 용도, 기타 용도)
조사 대상 기업 사례
Alkem Laboratories
Aquatic Remedies
Aspen API
Bionpharma Inc.
Blubell Pharma
Cadila Pharmaceuticals
Cipla Limited
Estrellas Life Sciences
Glenmark Pharmaceuticals
Gonane Pharma
HRV Global Life Sciences
LGM Pharma
Lupin Limited
Merck KGaA
Midas Pharma
Novo Nordisk A/S
Pfizer CentreOne
Teva Pharmaceutical Industries
Virtus Pharmaceuticals
Zydus Group
AI 통합
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
ksm
영문 목차
영문목차
Global Progesterone Market to Reach US$2.6 Billion by 2030
The global market for Progesterone estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2024-2030. Natural Progesterone, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Synthetic Progesterone segment is estimated at 9.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$346.3 Million While China is Forecast to Grow at 17.4% CAGR
The Progesterone market in the U.S. is estimated at US$346.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$559.8 Million by the year 2030 trailing a CAGR of 17.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.1% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.
Global Progesterone Market - Key Trends & Drivers Summarized
Why Is Progesterone Gaining Importance in Hormonal Therapy and Reproductive Health?
Progesterone has become a crucial hormone in the pharmaceutical industry, widely used in hormone replacement therapy (HRT), fertility treatments, and pregnancy support. As a key hormone involved in the menstrual cycle, pregnancy maintenance, and overall reproductive health, progesterone is prescribed for conditions such as infertility, polycystic ovary syndrome (PCOS), menopausal symptoms, and endometriosis. Additionally, it plays a vital role in reducing the risk of preterm birth in high-risk pregnancies. The growing prevalence of hormonal imbalances and reproductive health disorders has driven increased demand for progesterone-based medications, including oral capsules, injections, vaginal gels, and creams. The rising number of women opting for assisted reproductive technologies (ART) such as in-vitro fertilization (IVF) has further propelled market growth. Beyond reproductive health, progesterone is also being studied for its potential benefits in neuroprotection, bone health, and cancer therapy. With advancements in synthetic and bioidentical progesterone formulations, the market continues to expand, addressing diverse medical needs and improving patient outcomes.
What Challenges Are Affecting the Widespread Use of Progesterone Therapies?
Despite its significant medical applications, the progesterone market faces several challenges that impact accessibility, affordability, and patient adherence. One of the primary concerns is the side effects associated with progesterone therapy, including bloating, mood swings, headaches, and fatigue, which can lead to discontinuation in some patients. Additionally, the high cost of certain progesterone-based fertility treatments and hormone replacement therapies limits accessibility, particularly in low- and middle-income regions where healthcare affordability remains a concern. The regulatory landscape surrounding hormone therapies also presents challenges, as governments impose strict guidelines to ensure drug safety and efficacy, leading to longer approval timelines for new formulations. Furthermore, the market faces competition from alternative hormone therapies and natural supplements, with some patients opting for plant-based or bioidentical alternatives instead of conventional progesterone medications. Addressing these challenges requires continued research into safer, more tolerable formulations, improved affordability through generic alternatives, and increased patient education to enhance adherence and treatment efficacy.
How Are Innovations in Drug Delivery and Bioidentical Hormones Transforming Progesterone Therapy?
Advancements in pharmaceutical technology and hormone synthesis are revolutionizing progesterone therapy, making treatments more effective, convenient, and patient-friendly. The development of bioidentical progesterone, which mimics the body’s natural hormone structure, has improved tolerability and reduced the risk of adverse effects compared to synthetic alternatives. Novel drug delivery systems, including transdermal patches, sustained-release implants, and sublingual tablets, are enhancing patient compliance by offering more convenient administration methods with prolonged efficacy. Additionally, the introduction of progesterone-releasing intrauterine devices (IUDs) is providing long-term contraceptive and therapeutic benefits, particularly for women managing endometriosis or heavy menstrual bleeding. The integration of nanotechnology in drug formulations is also enhancing progesterone bioavailability, ensuring better absorption and effectiveness with lower dosages. As personalized medicine advances, AI-driven hormone therapy customization is being explored to tailor progesterone treatments based on individual hormonal profiles. These innovations are not only improving patient outcomes but also expanding the market potential of progesterone-based therapies in reproductive and hormonal health management.
What Is Driving the Growth of the Progesterone Market?
The growth in the progesterone market is driven by several factors, including the increasing prevalence of hormonal disorders, rising demand for assisted reproductive technologies, and advancements in bioidentical hormone therapy. The growing awareness of reproductive health and the expansion of fertility clinics worldwide have significantly contributed to the demand for progesterone-based treatments. Additionally, the rise in menopausal hormone therapy adoption among aging women is fueling market expansion, as progesterone plays a crucial role in managing menopause-related symptoms. Government initiatives and healthcare programs supporting maternal health and pregnancy care have also accelerated market growth, particularly in addressing preterm birth risks. The increasing availability of over-the-counter (OTC) progesterone creams and supplements is further expanding consumer access to hormone support products. As research continues to uncover new therapeutic applications for progesterone, including its potential role in neurology and oncology, the market is expected to witness sustained growth, offering innovative and personalized solutions for a wide range of health conditions.
SCOPE OF STUDY:
The report analyzes the Progesterone market in terms of units by the following Segments, and Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 44 Featured) -
Alkem Laboratories
Aquatic Remedies
Aspen API
Bionpharma Inc.
Blubell Pharma
Cadila Pharmaceuticals
Cipla Limited
Estrellas Life Sciences
Glenmark Pharmaceuticals
Gonane Pharma
HRV Global Life Sciences
LGM Pharma
Lupin Limited
Merck KGaA
Midas Pharma
Novo Nordisk A/S
Pfizer CentreOne
Teva Pharmaceutical Industries
Virtus Pharmaceuticals
Zydus Group
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Progesterone - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Menstrual Disorders and Hormonal Imbalances Throws the Spotlight on Progesterone-Based Therapeutics
Expansion of Assisted Reproductive Technologies (ART) Drives Demand for Progesterone in Fertility Treatments
Growth in Hormone Replacement Therapy (HRT) Adoption Among Postmenopausal Women Strengthens Business Case for Progesterone Products
Increased Use of Progesterone in Preterm Birth Prevention Accelerates Demand Across Maternal Health Applications
Surge in Demand for Bio-Identical Hormones Spurs Innovation in Plant-Derived and Natural Progesterone Formulations
Regulatory Support for Progesterone-Based Products in Reproductive Health Expands Prescription and OTC Opportunities
Advancements in Drug Delivery Systems Propel Development of Sustained-Release and Vaginal Progesterone Applications
Rising Awareness of Women's Health and Hormonal Wellness Drives Consumer Education and Market Expansion
Growing Prevalence of Polycystic Ovary Syndrome (PCOS) Generates Demand for Hormonal Regulation Therapies
Increased R&D in Neuroprotective and Cardiometabolic Benefits of Progesterone Expands Therapeutic Applications
Expansion of Personalized Medicine and Hormone Monitoring Platforms Enhances Precision in Progesterone Dosing
Emergence of Compounded Hormone Therapy Solutions Strengthens Niche Market for Custom Progesterone Prescriptions
Focus on Minimizing Side Effects and Enhancing Bioavailability Spurs Innovation in Micronized and Topical Formulations
Rising Geriatric Population and Focus on Longevity Medicine Sustains Demand for Hormonal Support Therapies
Integration of Progesterone in Combination Therapies for Endometriosis and Uterine Disorders Expands Use Cases
Growing Clinical Evidence Supporting Progesterone's Role in Brain Health Drives Research in Neurological Indications
Increased Availability of Low-Dose Progesterone Products Enhances Market Access for Preventive and Maintenance Use
Challenges in Supply Chain and Raw Material Sourcing Create Opportunities for Synthetic and Alternative Production Methods
Focus on Digital Health Platforms and Telemedicine Boosts Access to Progesterone Prescriptions and Patient Monitoring
Global Expansion of Women's Wellness Clinics and Integrative Gynecology Practices Drives Market Penetration
Partnerships Between Pharma Companies and Fertility Clinics Accelerate Progesterone Product Uptake in ART Cycles
Rising Demand for OTC Hormonal Supplements Spurs Regulatory Dialogue and Market Diversification in Consumer Health
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Progesterone Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Progesterone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Natural Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Natural Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Natural Progesterone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Synthetic Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Synthetic Progesterone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Synthetic Progesterone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Menopause Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Menopause Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Menopause Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Contraception Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Contraception Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Contraception Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Endometrial Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Endometrial Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Endometrial Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Dysfunctional Uterine Bleeding Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Dysfunctional Uterine Bleeding Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Dysfunctional Uterine Bleeding Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hyperplastic Precursor Lesions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Hyperplastic Precursor Lesions Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Hyperplastic Precursor Lesions Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Injectable-based Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Injectable-based Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Injectable-based Delivery Mode by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Suspended Form-based Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Suspended Form-based Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Suspended Form-based Delivery Mode by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Oral Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Oral Delivery Mode by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Oral Delivery Mode by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
JAPAN
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 61: Japan 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
CHINA
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: China Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 70: China 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: China Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 73: China 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
EUROPE
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Progesterone by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Progesterone by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Progesterone by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 82: Europe 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 85: Europe 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
FRANCE
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: France Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 91: France 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: France Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 94: France 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
GERMANY
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 100: Germany 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 103: Germany 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 109: Italy 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 112: Italy 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
UNITED KINGDOM
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: UK Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 118: UK 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: UK Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 121: UK 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 124: Spain 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 127: Spain 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 130: Spain 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 133: Russia 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 136: Russia 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 139: Russia 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of Europe 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 145: Rest of Europe 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 148: Rest of Europe 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Progesterone by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 151: Asia-Pacific 15-Year Perspective for Progesterone by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 154: Asia-Pacific 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 157: Asia-Pacific 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 160: Asia-Pacific 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
AUSTRALIA
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 163: Australia 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 166: Australia 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 169: Australia 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
INDIA
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: India Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 172: India 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: India Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 175: India 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: India Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 178: India 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 181: South Korea 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 184: South Korea 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 187: South Korea 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
LATIN AMERICA
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Progesterone by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Progesterone by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 199: Latin America 15-Year Perspective for Progesterone by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 202: Latin America 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 205: Latin America 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 208: Latin America 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 211: Argentina 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 214: Argentina 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 217: Argentina 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 220: Brazil 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 223: Brazil 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 226: Brazil 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 229: Mexico 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 232: Mexico 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 235: Mexico 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Latin America 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Latin America 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Latin America 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
MIDDLE EAST
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Progesterone by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Progesterone by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 247: Middle East 15-Year Perspective for Progesterone by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 250: Middle East 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 253: Middle East 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 256: Middle East 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 259: Iran 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 262: Iran 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 265: Iran 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 268: Israel 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 271: Israel 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 274: Israel 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 277: Saudi Arabia 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 280: Saudi Arabia 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 283: Saudi Arabia 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 286: UAE 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 289: UAE 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 292: UAE 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 295: Rest of Middle East 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 298: Rest of Middle East 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Middle East 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030
AFRICA
Progesterone Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Progesterone by Type - Natural Progesterone and Synthetic Progesterone - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Progesterone by Type - Natural Progesterone and Synthetic Progesterone Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 304: Africa 15-Year Perspective for Progesterone by Type - Percentage Breakdown of Value Sales for Natural Progesterone and Synthetic Progesterone for the Years 2015, 2025 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Progesterone by Application - Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 307: Africa 15-Year Perspective for Progesterone by Application - Percentage Breakdown of Value Sales for Menopause Application, Other Applications, Contraception Application, Endometrial Cancer Application, Dysfunctional Uterine Bleeding Application and Hyperplastic Precursor Lesions Application for the Years 2015, 2025 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Progesterone by Delivery mode - Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
TABLE 310: Africa 15-Year Perspective for Progesterone by Delivery mode - Percentage Breakdown of Value Sales for Injectable-based Delivery Mode, Suspended Form-based Delivery Mode and Oral Delivery Mode for the Years 2015, 2025 & 2030